Proteolysis-Targeting Chimeras in Cancer Therapy: Targeted Protein Degradation for Next-Generation Treatment
October 2025
in “
Cancer
”
New to GT20029? There is a guide in the encyclopedia. Read the guide → Studysummary This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
Proteolysis-targeting chimeras (PROTACs) are a promising advancement in cancer therapy, enabling targeted degradation of oncogenic proteins, including those previously considered "undruggable." They utilize the ubiquitin-proteasome system to selectively suppress disease-causing proteins with lower doses and reduced toxicity compared to traditional inhibitors. PROTACs have shown efficacy in treating various cancers, such as prostate and breast cancer, with candidates like ARV-110 and ARV-471 advancing in clinical trials. Despite challenges like optimizing pharmacokinetics and delivery, ongoing research is enhancing their potential as a next-generation platform for personalized cancer therapy. Additionally, GT20029 is in a Phase 1 clinical trial for androgenetic alopecia, targeting the androgen receptor through PROTAC-mediated degradation.
